• Phase 2 (Actuate-1801 Part 3B) trial meets primary endpoint and demonstrates a clinically meaningful increase in median overall survival (10.1 months vs 7.2 months; log-rank p=0.01) in previously untreated patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) receiving elraglusib/GnP
• Risk of death was reduced by 37% (HR=0.63) in patients treated with elraglusib/GnP
• Data featured as an oral presentation at the ASCO Annual Meeting
• Company plans to engage with FDA in the second half of 2025 to align on a path towards product registration
• Company to host KOL event today at 6:30 pm CDT to discuss 1801 Part 3B results

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.